ArticlePloS one2026
Community management: An effective model to reduce medication discontinuation rate in patients with schizophrenia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication discontinuation is highly prevalent among patients with schizophrenia and is associated with poor clinical outcomes. Although community-based management models have been implemented in China to support patients, recent evidence of their effectiveness in reducing medication discontinuation rates remains limited.
methodsIn this cross-sectional study, we surveyed 1,531 patients with schizophrenia under community management in Chengdu, China, using a multi-stage sampling approach. Data on treatment discontinuation (defined as cessation of all antipsychotics for >15 days without medical advice), socio-demographics, clinical characteristics, and service utilization were collected via face-to-face interviews. Univariate and multivariable logistic regression analyses were used to identify the factors associated with medication discontinuation.
resultsThe overall rate of medication discontinuation was 4.1%. Multivariable analysis identified several independent risk factors for discontinuation: weak stable disease state (adjusted odds ratio [aOR] = 2.70, 95% confidence interval [CI]: 1.34-5.24), lack of insight (aOR for partial vs. no insight = 0.25, 95% CI: 0.08-0.80; aOR for full vs. no insight = 0.18, 95% CI: 0.05-0.65), presence of noticeable side effects (aOR = 1.98, 95% CI: 1.05-3.64), and absence of regular follow-up (aOR for intermittent vs. no follow-up = 0.38, 95% CI: 0.20-0.72; aOR for regular vs. no follow-up = 0.22, 95% CI: 0.10-0.44).
conclusionCommunity management was associated with a low rate of medication discontinuation in patients with schizophrenia. Key modifiable factors, including disease stability, insight, medication side effects, and follow-up adherence should be prioritized in community-based interventions to further improve treatment continuity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.